KPTI Overview
Upcoming Projects (KPTI)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KPTI)
-
A Third Look: Discussing Karyopharm's Subgroup Analysis SIENDO Study in Patients with TP53 Wild Type Endometrial Cancer for Selinexor as Maintenance Therapy
Ticker: KPTI
Executed On: May 11, 2023 at 03:00 PM EDT -
A Second Look: Discussing Karyopharm's Subgroup Analysis SIENDO Study in Patients with TP53 Wild Type Endometrial Cancer for Selinexor as Maintenance Therapy
Ticker: KPTI
Executed On: May 09, 2023 at 03:00 PM EDT -
Discussing Karyopharm's Subgroup Analysis SIENDO Study in Patients with TP53 Wild Type Endometrial Cancer for Selinexor as Maintenance Therapy
Ticker: KPTI
Executed On: May 03, 2023 at 12:30 PM EDT -
A second view: Discussing the ASCO 2022 poster "A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis" from Karyopharm Therapeutics
Tickers: KPTI, INCY
Executed On: Apr 13, 2023 at 02:30 PM EDT -
Discussing the ASCO 2022 poster "A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis" from Karyopharm Therapeutics
Tickers: KPTI, INCY
Executed On: Apr 03, 2023 at 12:00 PM EDT -
Checking on the Launch of Xpovio in relapsed refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma
Ticker: KPTI
Executed On: Feb 24, 2022 at 04:30 PM EST
Expired Projects (KPTI)
-
How promising was the Karyopharm's STORM Phase 2b Topline Data for Multiple Myeloma Released on 9/6/16?
Ticker: KPTI
Execute By: Oct 06, 2016
Included with Membership
Upcoming & Overdue Catalysts (KPTI)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (KPTI)
-
Data from Phase 2/3 SEAL Trial Evaluating Selinexor Patients with Dedifferentiated Liposarcoma due Early 2017
Ticker: KPTI
Occurred on: Sep 20, 2017 -
Karyopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials
Ticker: KPTI
Occurred on: Mar 10, 2017 -
Phase 1/2 data of Selinexor - STOMP trial for Multiple Myeloma
Ticker: KPTI
Occurred on: Dec 05, 2016 -
Karyopharm's STORM Phase 2b Topline Data for Multiple Myeloma Expected Mid Year
Ticker: KPTI
Occurred on: Sep 06, 2016 -
Phase 2b preliminary topline data of Selinexor - SADAL trial for Diffuse Large B-Cell Lymphoma due Q4 2016
Ticker: KPTI
Occurred on: Sep 06, 2016
Strategic Initiatives (KPTI)
